KromaTiD Blog2022-04-06T13:19:00-06:00

KromaTiD’s Dark Lab Files: A Blog

KromaTiD’s Dark Lab Files: Under the CAR Hood

The design and manufacture of chimeric antigen receptor (CAR) T cells is fraught with complex hurdles. Some of these are encountered during production while others can only be inferred weeks or months after the cells are infused into a patient. These challenges have driven [...]

March 17, 2023|Tags: , , , |

KromaTiD’s Dark Lab Files: Designing CAR-T Cell Production for Scale

The pace at which autologous CAR-T cells can be manufactured has been an obstacle for this very powerful technology from the start. Producing a cutting-edge cell therapy product in less than two weeks may sound fast, but those are two weeks patients may not [...]

March 14, 2023|Tags: , , |

KromaTiD’s Dark Lab Files: Sleeping Beauty and CAR-T Manufacturing

Chimeric antigen receptor (CAR) T cells have tremendous promise for treatment of cancer and other conditions. Multiple CAR-T therapies have attained FDA approval in the US but a number of barriers continue to hinder their wide-scale use. One such impediment is the time and [...]

March 7, 2023|Tags: , , , |

KromaTiD’s Dark Lab Files: CAR-T Therapy vs. Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma (PDAC) represents greater than 90% of pancreatic cancer cases [1,2]. Early symptoms are relatively non-specific, with critical early treatment sometimes delayed after misdiagnoses for non-life-threatening conditions such as gallstones [3]. PDAC currently has an average 5-year survival rate of less than [...]

February 17, 2023|Tags: , , , , , , |

KromaTiD’s Dark Lab Files: How Tumor Cells Can Outlive CAR-T Cells

Cellular adoptive immunotherapies, such as CAR-T cells, are among the most effective tools in modern medicine’s toolbox for fighting cancer, yet tumor cells are nothing if not resilient. While these therapies have demonstrated very promising successes in recent years, cancer too has continued to [...]

February 10, 2023|Tags: , , , , |

KromaTiD’s Dark Lab Files: Genes of Interest in CAR-T Engineering

Multiple hurdles face developers of novel cell-based therapies, such as CAR-T, to successfully produce effective therapeutics. Following is a brief summary of some of the key challenges and how they are being addressed through the use of gene editing.   If the patient’s own T [...]

February 4, 2023|Tags: , , , |


Go to Top